SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 13G

 
Under the Securities Exchange Act of 1934
(Amendment No. __)*
 

Avidity Biosciences, Inc.

(Name of Issuer)
 

Common Stock, $0.0001 par value

(Title of Class of Securities)
 

05370A108

(CUSIP Number)
 

September 30, 2024

(Date of Event Which Requires Filing of This Statement)
 
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
þ Rule 13d-1(b)
¨ Rule 13d-1(c)
¨ Rule 13d-1(d)
 
(Page 1 of 7 Pages)

 

______________________________

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

CUSIP No. 05370A10813GPage 2 of 7 Pages

 

1

NAME OF REPORTING PERSON

Avoro Capital Advisors LLC

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) þ

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:		 5

SOLE VOTING POWER

9,935,792 (including 3,060,792 shares of Common Stock issuable upon exercise of pre-funded warrants)

6

SHARED VOTING POWER

0

7

SOLE DISPOSITIVE POWER

9,935,792 (including 3,060,792 shares of Common Stock issuable upon exercise of pre-funded warrants)

8

SHARED DISPOSITIVE POWER

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9,935,792 (including 3,060,792 shares of Common Stock issuable upon exercise of pre-funded warrants)

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

8.3%

12

TYPE OF REPORTING PERSON

OO, IA

         

 

 

CUSIP No. 05370A10813GPage 3 of 7 Pages

 

1

NAME OF REPORTING PERSON

Behzad Aghazadeh

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) þ

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH:		 5

SOLE VOTING POWER

9,935,792 (including 3,060,792 shares of Common Stock issuable upon exercise of pre-funded warrants)

6

SHARED VOTING POWER

0

7

SOLE DISPOSITIVE POWER

9,935,792 (including 3,060,792 shares of Common Stock issuable upon exercise of pre-funded warrants)

8

SHARED DISPOSITIVE POWER

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9,935,792 (including 3,060,792 shares of Common Stock issuable upon exercise of pre-funded warrants)

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

8.3%

12

TYPE OF REPORTING PERSON

IN

         

 

 

CUSIP No. 05370A10813GPage 4 of 7 Pages

 

Item 1 (a). NAME OF ISSUER
   
  Avidity Biosciences, Inc. (the “Issuer”)

 

Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
   
  10578 Science Center Drive, Suite 125, San Diego, CA 92121

 

Item 2(a). NAME OF PERSON FILING
   
  This statement is filed by: (i) Avoro Capital Advisors LLC, a Delaware limited liability company (“Avoro”), which provides investment advisory and management services and has acquired the securities of the Issuer solely for investment purposes on behalf of Avoro Life Sciences Fund LLC, a Delaware limited liability company, and (ii) Behzad Aghazadeh (“Dr. Aghazadeh,” and together with Avoro, the “Reporting Persons”), who serves as the portfolio manager and controlling person of Avoro.
   
  The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.

 

Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
   
  The address of the business office of each of the Reporting Persons is 110 Greene Street, Suite 800, New York, NY 10012.

 

Item 2(c). CITIZENSHIP
   
  Avoro is a Delaware limited liability company.  Dr. Aghazadeh is a United States citizen.

 

Item 2(d). TITLE OF CLASS OF SECURITIES
   
  Common Stock, $0.0001 par value (the “Common Stock”)

 

Item 2(e). CUSIP NUMBER
   
  05370A108

 

Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

 

  (a) ¨ Broker or dealer registered under Section 15 of the Act;
  (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
  (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
  (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;

 

CUSIP No. 05370A10813GPage 5 of 7 Pages

 

 

  (e) þ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
  (f) ¨

An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

 

  (g) þ

A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

 

  (h) ¨

A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

 

  (i) ¨

A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

 

  (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
  (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

 

 

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

specify the type of institution: _________________________________

 

Item 4. OWNERSHIP
   
  The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page and is incorporated herein by reference.
   
  The percentage set forth in Row 11 of this Schedule 13G is calculated based upon  117,121,397 shares of Common Stock outstanding, which is the sum of: (i) the 109,801,397 shares of Common Stock outstanding as of July 22, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the SEC on August 9, 2024; and (ii) the 7,320,000 shares of Common Stock issued in the public offering reported in the Issuer’s Current Report on Form 8-K filed with the SEC on August 15, 2024, and assumes the exercise of certain pre-funded warrants held by Avoro Life Sciences Fund LLC.
 
Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
   
  Not applicable.

 

Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
   
  See Item 2.  Avoro Life Sciences Fund LLC has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the Common Stock.

 

Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
   
  Not applicable.

 

CUSIP No. 05370A10813GPage 6 of 7 Pages

 

 

Item 8.

IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

Not applicable.

Item 9. NOTICE OF DISSOLUTION OF GROUP
   
  Not applicable.

 

Item 10. CERTIFICATION
   
  Each Reporting Person hereby makes the following certification:
   
  By signing below the Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

 

CUSIP No. 05370A10813GPage 7 of 7 Pages

 

SIGNATURES

After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

DATE: November 14, 2024  
   
AVORO CAPITAL ADVISORS LLC  
   
   
/s/ Scott Epstein  
Name:  Scott Epstein  
Title:    Chief Financial Officer
             & Chief Compliance Officer		  
   

/s/ Behzad Aghazadeh

  
BEHZAD AGHAZADEH  

 

 

 

EXHIBIT 1

JOINT FILING AGREEMENT
PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

DATE: November 14, 2024  
   
AVORO CAPITAL ADVISORS LLC  
   
   
/s/ Scott Epstein  
Name:  Scott Epstein  
Title:    Chief Financial Officer
             & Chief Compliance Officer		  
   

/s/ Behzad Aghazadeh

  
BEHZAD AGHAZADEH  

 

Avidity Biosciences (NASDAQ:RNA)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024 Avidity Biosciences 차트를 더 보려면 여기를 클릭.
Avidity Biosciences (NASDAQ:RNA)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024 Avidity Biosciences 차트를 더 보려면 여기를 클릭.